Clotrimazole (Bay b 5097): In Vitro and Clinical Pharmacological Studies

AUTOR(ES)

Burgess, M. A.

RESUMO

Clotrimazole (Bay b 5097) is a new synthetic antifungal drug with in vitro activity against Candida spp., Torulopsis glabrata, and Saccharomyces spp. Pharmacological studies in man after the oral administration of 1.5 and 3 g of clotrimazole produced mean peak concentrations in the serum of 1.16 and 1.29 μg/ml, respectively, 2 hr after administration. In six patients taking 1.5 g of clotrimazole every 6 hr, there was a progressive decline in the serum concentrations after administration of a dose on days 1, 4, and 8. Nine other patients begun on a similar schedule manifested gastrointestinal symptoms attributed to the clotrimazole and were unable to complete the study. Concentrations of active drug in the urine were less than 1% of the administered dose.

Documentos Relacionados

• In Vitro Antifungal Activity of Clotrimazole (Bay b 5097)
• In Vitro Sensitivity of Torulopsis glabrata to Amphotericin B, 5-Fluorocytosine, and Clotrimazole (Bay 5097)
• Chemotherapeutic Evaluation of Clotrimazole [Bay b 5097, 1 (o-Chloro-α-α-Diphenylbenzyl) Imidazole] 1
• In vitro activity of ciprofloxacin (Bay o 9867).
• In vitro susceptibility of anaerobic bacteria to ciprofloxacin (Bay o 9867).